سعر اتكوجليفلوزين 25مجم 30 قرص 2026

Empagliflozin 25 mg film-coated tablets (SGLT2 inhibitor antidiabetic), pack of 30 tablets (3 strips of 10), Atco Pharma.

• Adults with insufficiently controlled type 2 diabetes mellitus, as an adjunct to diet and exercise: as monotherapy when metformin is inappropriate due to intolerance, or in addition to other medicinal products for diabetes.Population: AdultsATCO Pharma (Egyptian package insert, English)
• Symptomatic chronic heart failure with reduced ejection fraction.Population: AdultsATCO Pharma (Egyptian package insert, English)

• Very common: hypoglycaemia (with sulphonylurea or insulin), volume depletion. Common: vaginal moniliasis, vulvovaginitis, balanitis and other genital infections, urinary tract infection, thirst, constipation, pruritus, rash, increased urination, increased serum lipids. Uncommon: urticaria, angioedema, dysuria, blood creatinine increased/GFR decreased, haematocrit increased. Rare: Fournier's gangrene, diabetic ketoacidosis.Egyptian label · ATCO Pharma (Egyptian package insert, English)

• Hypersensitivity to empagliflozin or to any of the excipients.Egyptian label · ATCO Pharma (Egyptian package insert, English)

• Diabetic ketoacidosis (rare, including life-threatening/fatal and atypical cases with blood glucose <250 mg/dl) has been reported with SGLT2 inhibitors; assess patients with nausea, vomiting, abdominal pain, thirst, dyspnoea, confusion or unusual fatigue; discontinue if suspected; interrupt treatment for major surgery or acute serious illness. Not for use in type 1 diabetes.Egyptian label · ATCO Pharma (Egyptian package insert, English)
• Assess renal function before initiation and periodically (at least yearly) and before starting concomitant medicines that may reduce renal function.Egyptian label · ATCO Pharma (Egyptian package insert, English)
• Risk of volume depletion/hypotension (e.g. patients on diuretics, elderly, known cardiovascular disease); consider interrupting in conditions causing fluid loss.Egyptian label · ATCO Pharma (Egyptian package insert, English)

• Thiazide and loop diureticsEmpagliflozin may add to the diuretic effect and increase the risk of dehydration and hypotension.ATCO Pharma (Egyptian package insert, English)
• Insulin and insulin secretagogues (e.g. sulphonylureas)Increased risk of hypoglycaemia; a lower dose of insulin or the secretagogue may be required.ATCO Pharma (Egyptian package insert, English)
• Inducers of UGT enzymes (e.g. rifampicin, phenytoin)Effect of UGT induction not studied; co-treatment with known UGT inducers is not recommended (potential decreased efficacy); if co-administration is necessary, monitor glycaemic control.ATCO Pharma (Egyptian package insert, English)

• No data from use in pregnant women; as a precaution, avoid use during pregnancy.Egyptian label · ATCO Pharma (Egyptian package insert, English)
• No human data on excretion into milk; a risk to newborns/infants cannot be excluded; should not be used during breastfeeding.Egyptian label · ATCO Pharma (Egyptian package insert, English)

• Empagliflozin: Inhibits SGLT2 in the proximal renal tubule, reducing renal reabsorption of filtered glucose and lowering the renal threshold for glucose, thereby increasing urinary glucose excretion (US label).

Store at or below 30°C in a dry place; shelf life 2 years; cartons of AL/AL strips of 10 tablets.